We have previously demonstrated the effects of Fyn/SFK inhibition using saracatinib (SAR; AZD0530), a selective pharmacological inhibitor of SFK/Fyn in kainic acid (KA) and diisopropylfluorophosphate (DFP) models of epilepsy (Sharma et al., 2018a,2021a; Gage et al., 2021a,2022b). This evidence concerns the gene FYN and epilepsy.